Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Significant Drop in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large drop in short interest in October. As of October 15th, there was short interest totaling 19,178 shares, a drop of 81.8% from the September 30th total of 105,501 shares. Based on an average daily volume of 224,827 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DSNKY. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Daiichi Sankyo currently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

Daiichi Sankyo stock opened at $16.47 on Wednesday. The company has a 50-day simple moving average of $17.81 and a 200-day simple moving average of $17.76. Daiichi Sankyo has a one year low of $14.98 and a one year high of $26.80.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts predict that Daiichi Sankyo will post 0.93 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.